I agree. There will be some switches. Hopefully a lot. But Vascepa has been on the market for 11 years. A switch in the formulary for some low-income Medicare patients is not going to create a landslide of new scripts, especially when there is zero sales, marketing, or education efforts being put forth by Amarin.
It didn't happen with the Healthnet settlement. It didn't happen with the Texas or NY formulary changes. I don't see this as any different.
News 
Market Data 
Discover 
